Meeting
2018 ASCO Annual Meeting
Phase 1b/2, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced melanoma who are naïve to anti-PD-1 therapy.
Authors
Antoni Ribas
UCLA Johnson Comprehensive Cancer Center, Los Angeles, CA
Antoni Ribas , Mohammed M. Milhem , Christopher J. Hoimes , Asim Amin , Inderjit Mehmi , Christopher D. Lao , Robert Martin Conry , Montaser F. Shaheen , Sekwon Jang , April K.S. Salama , Sanjeev Deva , Theresa Michelle Medina , Emmett V. Schmidt , Abraham C.F. Leung , Biao Xing , Robert Janssen , Georgina V. Long
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT02521870
Citation
J Clin Oncol 36, 2018 (suppl; abstr 9513)
DOI
10.1200/JCO.2018.36.15_suppl.9513
Abstract #
9513
Poster Bd #
340
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Design and rationale of MASTERKEY-115 phase II trial of talimogene laherparepvec (T-VEC) with pembrolizumab (pembro) in patients with advanced melanoma who progressed on prior anti-programmed cell death-1 (anti-PD-1) therapy.
First Author: Jason Alan Chesney
Poster
2019 ASCO Annual Meeting
Phase 1b/2, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced melanoma who are naïve to anti-PD-1 therapy.
First Author: Mohammed M. Milhem
Poster
2020 ASCO Virtual Scientific Program
AST-008: A novel approach to TLR9 agonism with PD-1 blockade for anti-PD-1 refractory Merkel cell carcinoma (MCC) and cutaneous squamous cell carcinoma (CSCC).
First Author: Mohammed M. Milhem
Poster
2020 Gastrointestinal Cancers Symposium
![Phase Ib study to test the safety and activity of pembrolizumab (anti-PD-1) and trebananib (angiopoietin-2 inhibitor [Ang-2]) in patients with advanced solid tumors: Updated analysis of the colorectal cancer (CRC) cohort.](https://d201v5jt9ylckg.cloudfront.net/255/14596/182760/182760_poster_pv.jpg)
Phase Ib study to test the safety and activity of pembrolizumab (anti-PD-1) and trebananib (angiopoietin-2 inhibitor [Ang-2]) in patients with advanced solid tumors: Updated analysis of the colorectal cancer (CRC) cohort.
First Author: Osama E. Rahma